Melanotan I and Melanotan II Research: Related Melanocortin Analogues, Distinct Evidence
The short answer
“Melanotan I” and “Melanotan II” are related melanocortin analogues, but they are not interchangeable names for the same evidence base. Afamelanotide, an analogue associated historically with Melanotan I development, has been studied and authorized as a specific implant for a specific indication. Melanotan II is a distinct cyclic analogue with only limited early human research.
Names used in online markets can be inconsistent. A label using “Melanotan I” does not establish that the material is the authorized afamelanotide implant, and evidence for that implant does not transfer to another formulation.
Melanocortin receptors
Melanocortin peptides can interact with several receptor subtypes involved in pigmentation and other physiological systems. Structural differences can change receptor activity, pharmacokinetics and adverse-effect profiles. That is why a shared family name is not enough for scientific comparison.
Afamelanotide evidence is product-specific
Randomized trials studied a controlled-release afamelanotide implant in erythropoietic protoporphyria, a rare phototoxic disorder. The measured outcomes involved light tolerance and phototoxic reactions in that population. Regulatory authorization is tied to that product, formulation and indication.
This evidence does not validate a generic “Melanotan I” vial, a different route, tanning claims or unsupervised use. Pharmaceutical identity requires more than a similar peptide name.
Melanotan II evidence is different
An early phase human study evaluated Melanotan II in a small number of participants and recorded pigmentation and adverse effects. Small early studies are useful for initial pharmacology, but they cannot establish broad safety, uncommon risks, long-term outcomes or consumer use.
Health Canada has warned that unauthorized injectable peptides sold online, including products marketed as Melanotan I and II, may pose serious risks and have not been assessed for safety, efficacy or quality.
Key points
- Melanotan I, afamelanotide and Melanotan II should not be collapsed into one evidence claim.
- Afamelanotide implant evidence is formulation- and indication-specific.
- Melanotan II human evidence is limited and early.
- Similar naming does not establish chemical identity, quality or equivalence.
- Regulatory authorization of one product does not validate a separate research material.
What this article does not establish
This article does not establish tanning, photoprotection, sexual-function or other benefits for an AURAPEP product. It does not establish safety and does not provide instructions for human use.
Primary and authoritative references
- Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. PubMed 26132941.
- Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. PubMed 8637402.
- U.S. Food and Drug Administration. Orphan Drug Designations and Approvals: afamelanotide. FDA record.
- Health Canada. Think twice before injecting peptides bought online. Health Canada advisory.